Arcutis Biotherapeutics presents data on roflumilast cream 0.05% improving mild to moderate atopic dermatitis in 2-5 year-olds.
Arcutis Biotherapeutics presents late-breaking data from INTEGUMENT-PED study, showing roflumilast cream 0.05% improved mild to moderate atopic dermatitis in 2-5 yr-olds, including disease clearance in 1 week and itch reduction within 24 hours. The treatment was well-tolerated, with low incidence of adverse events. If approved, it will be a new steroid-free option for young children with atopic dermatitis.
March 10, 2024
3 Articles